Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 1/2015

01-03-2015 | Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Drug Management in the Elderly IBD Patient

Authors: Marina Kim, DO, Seymour Katz, MD FACP MACP, Jesse Green, MD FACG

Published in: Current Treatment Options in Gastroenterology | Issue 1/2015

Login to get access

Opinion statement

Managing inflammatory bowel disease (IBD) in a world of immunomodulators and biologics is complex enough, but managing the elderly IBD patient is further confounded by multiple comorbidities, polypharmacy with drug–drug interactions, and cognitive mobility/motility disturbances. Social and insurance coverage issues also always lurk in the background. All of these factors summate into a daunting challenge for the clinician. In this review, we aim to describe important considerations when prescribing to an elderly patient with IBD, taking into account costs of medications, drug interactions, the aging body’s effect on pharmacokinetics, and the effect of aging on the immune system. Adverse effects and drug–drug interactions are expounded upon in detail specific for the aging adult with IBD in an effort to assist the clinician in the decision-making process.
Literature
1.
2.
Molodecky NA et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. e42; quiz e30.CrossRefPubMed
3.
4.
Loftus Jr EV et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998;114(6):1161–8.CrossRefPubMed
5.••
Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm Bowel Dis. 2013;19(10):2257–72. This article discusses how the decline in immune function requires consideration of medical therapy in IBD.CrossRefPubMed
6.
Manosa M, Calafat M, de Francisco R, et al. Phenotypic characteristics and use of therapeutic resources in elderly-onset inflammatory bowel disease: a multicenter, case-control study. In Digestive Disease Week 2014.
7.
Loftus CG et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13(3):254–61.CrossRefPubMed
8.
Charpentier C et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423–32.CrossRefPubMed
9.
Ha CY et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8(8):682–7. e1.CrossRefPubMedCentralPubMed
10.
Nguyen GC, Bernstein C, Benchimol EI. Risks of Hospitalizations and Surgery in Elderly-Onset Inflammatory Bowel Disease: A Population Based Study. In Digestive Disease Week 2014.
11.
12.
Nelson DR et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12(1):1–51.CrossRefPubMed
13.
Peterson JA, Graham SE. A close family resemblance: the importance of structure in understanding cytochromes P450. Structure. 1998;6(9):1079–85.CrossRefPubMed
14.
Smith G et al. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998;28(12):1129–65.CrossRefPubMed
15.
Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. Genome Biol. 2000;1(6): p. REVIEWS3003.
16.
Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther. 1995;68(3):385–424.CrossRefPubMed
17.
Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review). Int J Mol Med. 1999;3(3):227–38.PubMed
18.
Swedko PJ et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163(3):356–60.CrossRefPubMed
19.
Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005;11(6):449–60.CrossRefPubMed
20.
Aymanns C et al. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010;5(2):314–27.CrossRefPubMed
21.
Cooper E, Zhang Z, Raftos DA, Habicht GS, Beck G, Connors V, et al. When did communication in the immune-system begin. Int J Immunopathol Pharmacol. 1994;7(3):203–17.
22.
Cakman I et al. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev. 1996;87(3):197–209.CrossRefPubMed
23.
24.
Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9(1):11–23.CrossRefPubMedCentralPubMed
25.
Chapman RH et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25(10):885–92.CrossRefPubMed
26.
Parlan AH, Ha C. Severe polypharmacy and major medication interactions are associated with increasing age and comorbidities among IBD patients. Gastroenterology. 2013;144(suppl.1)( S11 Abstract Su1130).
27.
Parian AM, Ha CY. Severe polypharmacy and major medication interactions are associated with increasing age and comorbidity among inflammatory bowel disease patients. Gastroenterology. 2013;144(5, Supplement 1): p. S-406.
28.
"Prices, Coupons and Information - GoodRx." Prices, Coupons and Information. N.p., n.d. Web. 06 Nov. 2014.
29.
30.
Prescribing information. Apriso (mesalamine). Morrisville, NC: Salix Pharmaceuticals, Inc., 2008.
31.
Prescribing information. Asacol (mesalamine). Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc., October 2007.
32.
Prescribing information. Lialda (mesalamine). Wayne, PA: Shire US Inc., January 2007.
33.
Ford AC, Khan K, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroentrol. 2011;106:2070–7.CrossRef
34.
Kane SV, Summer M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56:3463–70.CrossRefPubMed
35.
Sandborn WJ et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138(4):1286–96. 1296 e1-3.CrossRefPubMed
36.
Reguiero M, Loftus Jr E, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979–94.CrossRef
37.
Safdi M, DeMicco M, Sninsky C, et al. A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.PubMed
38.
Marshall JK et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;1, CD004115.PubMed
39.
Rao SS, C American College of Gastroenterology Practice Parameters. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol. 2004;99(8):1585–604.CrossRefPubMed
40.
Boyle DJ et al. The effects of age and childbirth on anal sphincter function and morphology in 999 symptomatic female patients with colorectal dysfunction. Dis Colon Rectum. 2012;55(3):286–93.CrossRefPubMed
41.
Hall S, Rindone JP. A case of sulphasalazine potentiating the hypoprothombinemic effect of warfarin resulting in bleeding. J Clin Pharm Ther. 2011;36(2):246–8.CrossRefPubMed
42.
Teefy AM, Martin JE, Kovacs MJ. Warfarin resistance due to sulfasalazine. Ann Pharmacother. 2000;34(11):1265–8.CrossRefPubMed
43.
Feagan BG et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342(22):1627–32.CrossRefPubMed
44.
45.
Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13(5):629–38.CrossRefPubMed
46.
Firwana BM et al. Nephrotic syndrome after treatment of Crohn's disease with mesalamine: case report and literature review. Avicenna J Med. 2012;2(1):9–11.CrossRefPubMedCentralPubMed
47.
Singh M et al. Gastrointestinal drug interactions affecting the elderly. Clin Geriatr Med. 2014;30(1):1–15.CrossRefPubMed
48.
Kornbluth A, Sachar DB, G. Practice Parameters Committee of the American College of. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23. quiz 524.CrossRefPubMed
49.
Shen B et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7(4):301–5.CrossRefPubMed
50.
Bito M et al. The mechanisms of insulin secretion and calcium signaling in pancreatic beta-cells exposed to fluoroquinolones. Biol Pharm Bull. 2013;36(1):31–5.CrossRefPubMed
51.
Chou HW et al. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis. 2013;57(7):971–80.CrossRefPubMed
52.
Lexi-Comp OnlineTM, Hudson, Ohio: Lexi-Comp, Inc.; April 2014.
53.
Howard-Thompson A et al. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother. 2008;6(1):33–6.CrossRefPubMed
54.
Juneja M et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57(9):2408–15.CrossRefPubMed
55.
Lichtenstein GR et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409–22.CrossRefPubMedCentralPubMed
56.
Ha CY, Katz S. Clinical implications of ageing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2014;11(2):128–38.CrossRefPubMed
57.
Brassard P, et al. "Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases." Am J Gastroenterol. 2014;109(11):1795–802.
58.
Suzuki Y et al. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohn’s Colitis. 2013;7(3):239–47.CrossRef
59.
Ford AC et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–9. quiz 600.CrossRefPubMed
60.
Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30(1):60–5.CrossRefPubMed
61.
Akerkar GA et al. Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol. 1997;92(3):461–4.PubMed
62.
Ananthakrishnan AN et al. Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci. 2011;56(1):176–82.CrossRefPubMed
63.
Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Curr Opin Gastroenterol. 2002;18(4):428–34.CrossRefPubMed
64.
Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis. 2004;10(5):578–83.CrossRefPubMed
65.
Greenwald DA, Brandt LJ. Inflammatory bowel disease after age 60. Curr Treat Options Gastroenterol. 2003;6(3):213–25.CrossRefPubMed
66.
Rodriguez-D'Jesus A, Casellas F, Malagelada JR. [Epidemiology of inflammatory bowel disease in the elderly]. Gastroenterol Hepatol. 2008;31(5):269–73.CrossRefPubMed
67.
Neurath MF et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3(10):1007–14.CrossRefPubMed
68.
Dubinsky MC et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705–13.CrossRefPubMed
69.
Smith MA et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohn’s Colitis. 2012;6(9):905–12.CrossRef
70.
Blaker PA et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013;86(4):539–47.CrossRefPubMed
71.
Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohn’s Colitis. 2010;4(4):444–9.CrossRef
72.
de Boer NK et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102(12):2747–53.CrossRefPubMed
73.
Gao X, et al. "The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients." Eur J Gastroenterol Hepatol. 2012;24(8):958–64.
74.
Daperno M et al. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30(8):843–53.CrossRefPubMed
75.
Chisick L, Oleschuk C, Bernstein CN. The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease. Can J Gastroenterol. 2013;27(1):39–43.PubMedCentralPubMed
76.
Smith MA et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32(2):119–30.CrossRefPubMed
77.
Beaugerie L et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.CrossRefPubMed
78.
79.
Peyrin-Biroulet L et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–8. e1-5.CrossRefPubMed
80.••
Cottone M et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30–5. An Italian study from 2000-2009 found an increased rate of severe infections in elderly patients with IBD with a 10% mortality rate as compared to younger patients treated with biologics.CrossRefPubMed
81.
Billioud V, Peyrin-Biroulet L. Can elderly people be treated safely with anti-TNF agents? Inflamm Bowel Dis. 2012;18(3):594–5.CrossRefPubMed
82.
Shen H, Lipka S, Katz S. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience. J Crohn’s Colitis. 2014;8(8):898–9.CrossRef
83.
Ortega TL, Vermeire S, Vallet V, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Digestive Disease Week 2014. Abstract Mo1179.
84.
Tofani C, Valentin T, Tierney A, et al. IBD is an independent risk factor for major infections complications in elderly patients. In Digestive Disease Week 2014. 2014.
85.
Desai A, Zator ZA, de SIlva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;19:309–15.CrossRef
86.••
Lichtenstein GR et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(7):1051–63. Biologics such as infliximab have been shown to have a safer profile than immunomodulators, not significantly increasing the incidence of infection, mortality, or malignancy. In contrast, patients treated with immunomodulators as opposed to placebo had a higher incidence of malignancy.CrossRefPubMedCentralPubMed
87.
Burmester GR et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517–24.CrossRefPubMedCentralPubMed
88.
89.
Keihanian S, Glover S. Ustekinumab for the Treatment of Crohn's Disease, in 79th Annual Scientific Meeting of the American College of Gastroenterology. Am J Gastroenterol. 2014
90.
Manten E, Green JA, Bartholomew C. Primary care considerations in the management of inflammatory bowel disease patients. Practical Gastro. 2012;49.
91.••
Ha C, Katz S. Management of inflammatory bowel disease in the elderly: do biologicals offer a better alternative? Drugs Aging. 2013;30(11):871–6. This article discusses the safety and efficacy of biologics in the treatment of IBD in the elderly patient.CrossRefPubMed
Metadata
Title
Drug Management in the Elderly IBD Patient
Authors
Marina Kim, DO
Seymour Katz, MD FACP MACP
Jesse Green, MD FACG
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 1/2015
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-014-0039-2

Other articles of this Issue 1/2015

Current Treatment Options in Gastroenterology 1/2015 Go to the issue

Esophagus (E Dellon, Section Editor)

Optimizing Patient Selection and Outcomes for Surgical Treatment of GERD and Achalasia

Esophagus (E Dellon, Section Editor)

Translating New Developments in Eosinophilic Esophagitis Pathogenesis into Clinical Practice

Inflammatory Bowel Disease (G Lichtenstein, Section Editor)

Management of Severe Ulcerative Colitis

Colon (C Burke, Section Editor)

Clostridium Difficile Infection: Risk Factors, Diagnosis and Management

Colon (C Burke, Section Editor)

Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?

Colon (C Burke, Section Editor)

Diverticular Disease: Paradigm Shifts in Pathogenesis and Treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits